dry eye

Targeting dry eye in glaucoma patients
Targeting dry eye in glaucoma patientsA poor ocular surface is a common condition in glaucoma patients due to the incidence of dry eye, age, and use of benzalkonium chloride (BAK). Poor compliance with glaucoma therapy can result. Use of point-of-care testing can help identify patients with a poor ocular surface and drive treatment decisions. Treatment options, including surgical, are discussed.
Using neurostimulation to treat dry eye
Using neurostimulation to treat dry eyeNeurostimulation could be the “next big thing” in dry eye disease (DED). A new neurostimulation device called TrueTear (Allergan) is a patient-directed, non-pharmacologic option.
Numbers transform dry eye treatment for symptomatic, asymptomatic patientsAdding objective point-of-care dry eye diagnostics to your practice has deep, measurable effects, including more accurate and consistent IOL power calculations.
Reviewing anterior segment ARVO 2017 postersSo much basic science research is presented at this meeting, and most of it will be years before it makes its way to clinical trials. Let’s concentrate on research that might be of use to us in the exam room very soon.
Dry eye checklist may help ODs treat patients more efficiently
Dry eye checklist may help ODs treat patients more efficientlyScott Schachter, OD, discusses dry eye and how incorporating a dry eye checklist may help improve patient treatment.
ARVO 2017 showcases vision research advancesAdvances in presbyopia, dry eye and allergy, and age-related macular degeneration filled this year’s meeting of the Association for Research in Vision and Ophthalmology.
Building on cyclosporine for dry eyeA phase II study investigating a novel topical cyclosporine product (CyclASol, Novaliq) formulated in a semifluorinated alkane (SFA) vehicle showed promising efficacy, safety, and tolerability. Planning is ongoing for the phase III trial of cyclosporine in the SFA technology.
Novel therapies abound in pipelineThe importance of novel therapies for ocular disease is a given. However, as most novel therapies are financed by the private sector, it is fortunate that investors find ophthalmology a worthwhile investment.
Understanding the role of inflammation in dry eye
Understanding the role of inflammation in dry eyeOptometry Times Editorial Advisory Board members Leslie E. O’Dell. OD, FAAO, and Scott Hauswirth, OD, FAAO, discuss their recent lecture on inflammation and the role it plays in ocular surface diseases at the American Optometric Association’s Optometry’s Meeting in Washington, DC.
How tear proteomics can help optometryODs undervalue ocular point-of-care tear testing